Product Information

MATZIM LA 300 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $1.7877 per EA under NDC 52544069330. Its NADAC has been published 591 times since Nov 28, 2013.

FDA first approved this application on Mar 15, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

MATZIM LA 300 MG TABLET

Diltiazem Hydrochloride
$1.7877per EA

Strength

300 mg/1

NDC

52544069330

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

DILTIAZEM HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA077686

FDA Approved

3/15/2010

TE Code

AB

On Market Since

3/28/2011

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A4 Inhibitors

Price Statistics

The NADAC for MATZIM LA 300 MG TABLET has been published 591 times since Nov 28, 2013, and over the history we have for it it has declined 46.0%. The table below summarizes its recorded NADAC range and movement.

Current price$1.7877 per EA
All-time high$3.3997 (Jun 15, 2016)
All-time low$1.2965 (Jan 21, 2026)
52-week high$2.9349
52-week low$1.2965
Median price$3.1678
Average price$2.9657
Largest weekly change+33.9% (Oct 23, 2024)
Weeks tracked591
Tracking sinceNov 28, 2013

Price History

1W

-2.0%

1M

+0.4%

3M

+0.7%

6M

+18.9%

1Y

-39.1%

3Y

-42.7%

5Y

-43.6%

All

-46.0%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 1%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of MATZIM LA 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for MATZIM LA 300 MG TABLET, manufactured by Actavis Pharma, Inc., is $1.7877 per EA (NDC 52544069330), effective Aug 19, 2026.

How has the price of MATZIM LA 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for MATZIM LA 300 MG TABLET has declined 46.0%. It has been tracked across 591 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for MATZIM LA 300 MG TABLET?

Since Nov 28, 2013, the NADAC for MATZIM LA 300 MG TABLET has ranged from a low of $1.2965 (Jan 21, 2026) to a high of $3.3997 (Jun 15, 2016), with a median of $3.1678 per EA.

Are there cheaper alternatives to MATZIM LA 300 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DILTIAZEM 24H ER(LA) 300 MG TB, is $1.7746 per EA — about 1% below MATZIM LA 300 MG TABLET.

Who manufactures MATZIM LA 300 MG TABLET?

MATZIM LA 300 MG TABLET (NDC 52544069330) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.